Business, energy, technology, markets and global industry news from Business News Today

drug discovery

PharmaDeviceNews drug discovery
Pharma & Biotech

Contineum Therapeutics paper sharpens PIPE-791 case, but Phase 2 IPF data remain decisive

Discover why Contineum Therapeutics’ PIPE-791 paper strengthens the LPAR1 case while Phase 2 IPF data remain the decisive clinical test.

Read More
Representative image of scientists reviewing oncology research data in a modern biopharma laboratory, reflecting Pfizer and Innovent Biologics’ $10.5 billion collaboration and the growing race to develop antibody-drug conjugates and multispecific cancer therapies.
Pharma & Biotech

Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?

Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.

Read More
Representative image of pharmaceutical executives and scientists reviewing drug discovery data in a modern research setting, reflecting Eli Lilly and Haisco Pharmaceutical’s multi-program collaboration and the growing role of China-originated innovation in global pharma licensing.
Pharma & Biotech

Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?

Eli Lilly’s Haisco deal could be worth over $3 billion. Find out why China-originated drug discovery is becoming harder to ignore.

Read More
Representative image of an advanced mass spectrometry laboratory, highlighting how Thermo Fisher Scientific’s next-generation Orbitrap innovations at ASMS 2026 could support faster drug discovery, deeper proteomics research and the development of new therapies.
Pharma & Biotech

Why Thermo Fisher Scientific’s ASMS 2026 launch matters for drug discovery workflows

Thermo Fisher Scientific unveils new Orbitrap platforms at ASMS 2026. Find out how they could reshape drug discovery workflows today!

Read More
Pharma & Biotech

Why Aphios’ Bryoid composition patent matters beyond Alzheimer’s disease research

Aphios has a new Bryoid patent allowance. The bigger test is whether marine-derived PKC biology can move from IP promise to clinical proof.

Read More
Features & Analysis

Drug discovery has an AI problem. Clicklinks thinks the answer is connection, not just algorithms

Find out how Sanyou Bio’s Clicklinks platform could reshape AI-led drug discovery by linking biotech, CRO, CDMO and preclinical resources.

Read More
Pharma & Biotech

Can Anthropic’s Claude help Bristol Myers Squibb speed up medicine discovery and delivery?

Bristol Myers Squibb is moving AI from pilots to enterprise scale. Claude’s real test is governance, data trust and drug development impact.

Read More
Representative image: Researchers review AI-enabled virtual screening data and molecular models in a drug discovery lab as Concept Life Sciences and OpenBench push a success-based model for faster, lower-risk biotech hit validation.
Pharma & Biotech

Concept Life Sciences expands drug discovery model as OpenBench brings AI-enabled screening scale

Biotechs need faster hits with less upfront risk. Concept Life Sciences and OpenBench are testing whether success-based discovery can deliver.

Read More
Pharma & Biotech

Why Bristol Myers Squibb’s $15.2bn Hengrui alliance signals a pipeline reset

Big Pharma needs faster pipelines. Bristol Myers Squibb’s Hengrui pact shows why China’s R&D engine is becoming harder to ignore.

Read More
Representative image of a biopharmaceutical laboratory workflow showing HEK293 functional cell line research, assay development and compliance documentation, as ACROBiosystems streamlines global licensing access to support faster drug discovery and regulated R&D operations.
Pharma & Biotech

ACROBiosystems makes HEK293 functional cell lines easier to use in global R&D workflows

HEK293 tools are everywhere, but licensing slows teams down. ACROBiosystems is turning compliance clarity into an R&D advantage.

Read More